| { |
| "task_id": "genome_001", |
| "domain": "KEGG_BRITE", |
| "autonomy_type": "ordered table", |
| "oracle_output_cardinality": 3, |
| "instruction": "I am compiling a reference list of medications for ulcerative colitis for in-hospital use. From the immunosuppressants cataloged in KEGG, I want to select those drug entries that have been approved in Japan by the end of June 2025 and that carry explicit CYP-related metabolism information or CYP inhibition indications. Please proceed in the following order: first, within the scope of KEGG immunosuppressants for ulcerative colitis, screen for drug entries approved in Japan by the end of June 2025; then check whether each entry has explicit CYP-related metabolism information or CYP inhibition indications, retaining only qualifying entries. Next, record each entry's Japanese therapeutic classification code, ATC code, corresponding target branch, and Japan first approval date. Finally, output a single-line string sorted by Japan first approval date from earliest to latest, in the format <DRUG_ID>|<JP_class>|<ATC>|<Target_branch>|<JP_date>; separate entries with commas; if no qualifying entries exist, output NONE.", |
| "start_url": "https://www.genome.jp/kegg/brite.html", |
| "output_format": "Output a single-line string sorted by Japan first approval date from earliest to latest, in the format <DRUG_ID>|<JP_class>|<ATC>|<Target_branch>|<JP_date>; separate entries with commas; if no qualifying entries exist, output NONE.", |
| "oracle_answer": "D09783|3999|L04AF01|JAK1/JAK2/JAK3/TYK2|2013/3/25,D11048|3999|L04AF03|JAK1|2020/1/23,D10931|2399|L04AE05|S1PR1/S1PR4/S1PR5|2025/6/24", |
| "metadata": { |
| "State-Gated Retrieval": [ |
| "Within the scope of KEGG immunosuppressants for ulcerative colitis, retain only entries approved in Japan by 2025-06-30 and that carry explicit CYP-related metabolism information or CYP inhibition indications.", |
| "Candidate drugs must be re-verified against the corrected UC drug list for Japanese therapeutic classification, ATC, target branch, CYP evidence, and Japan first approval date.", |
| "Finally, output sorted by Japan first approval date from earliest to latest." |
| ], |
| "dependency_type": "Data + Control", |
| "intra_chain": true, |
| "inter_chain": true, |
| "data_dependency": [ |
| "KEGG disease H01466 and linked drug entries yield the ulcerative-colitis immunosuppressant candidate set", |
| "each candidate drug entry yields Japanese class, ATC, target branch, CYP metabolism/inhibition evidence, and Japan approval date", |
| "final rows are produced only after the full UC candidate set is determined and every candidate is checked against CYP evidence and PMDA timing" |
| ], |
| "control_dependency": [ |
| "the candidate set must include Japanese class 3999 UC drugs when the disease page exposes them rather than being limited to 2399 alone", |
| "target / CYP / PMDA validation must be applied across the full candidate set rather than only the old 2399 subset", |
| "entries without explicit CYP evidence may be dropped only after the full candidate set has been established" |
| ], |
| "freeze": { |
| "historical_window": "KEGG ulcerative-colitis drug candidates with Japan approvals on or before 2025-06-30; current drug-entry annotations provide target, CYP, and Japan-class metadata" |
| }, |
| "answer_type": "multi-row ordered table" |
| }, |
| "rubric": { |
| "inclusion_conditions": [ |
| "Within the scope of KEGG immunosuppressants for ulcerative colitis, retain only entries approved in Japan by 2025-06-30 and that carry explicit CYP-related metabolism information or CYP inhibition indications.", |
| "Candidate drugs must be re-verified against the corrected UC drug list for Japanese therapeutic classification, ATC, target branch, CYP evidence, and Japan first approval date.", |
| "Finally, output sorted by Japan first approval date from earliest to latest." |
| ], |
| "exclusion_conditions": [ |
| "Exclude results that incorrectly lock the upstream scope to the 2399 digestive branch without falling back to the full UC drug list.", |
| "Exclude entries without explicit CYP-related metabolism information or CYP inhibition indications.", |
| "Exclude entries with a Japan approval date after 2025-06-30 or that are not within the KEGG UC immunosuppressant scope." |
| ], |
| "normalization": { |
| "field_separator": "|", |
| "record_separator": ",", |
| "schema": [ |
| "DRUG_ID", |
| "JP_class", |
| "ATC", |
| "Target_branch", |
| "JP_date" |
| ], |
| "dedup_key": "DRUG_ID", |
| "JP_date": "use the canonical KEGG-style date format YYYY/M/D with no zero-padding requirement beyond the source value", |
| "Target_branch": "emit the most specific target branch visible in the source path; when multiple parallel branches survive, join them with `/`", |
| "sorting_or_selection": { |
| "primary": "JP_date ascending", |
| "secondary": "DRUG_ID ascending" |
| } |
| } |
| } |
| } |
|
|
